{"id":"NCT00195715","sponsor":"Abbott","briefTitle":"Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease","officialTitle":"A Multi Center, Open Label Study of the Human Anti TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2006-03","completion":"2008-12","firstPosted":"2005-09-20","resultsPosted":"2010-01-07","lastUpdate":"2011-07-12"},"enrollment":777,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[],"summary":"To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.","primaryOutcome":{"measure":"Percentage of Subjects Achieving Clinical Remission","timeFrame":"Week 156","effectByArm":[{"arm":"Open-label Adalimumab","deltaMin":69.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":111,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Hungary","Italy","Netherlands","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["29380251","22704916","19201775"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":296,"n":777},"commonTop":["Crohn's disease","Nasopharyngitis","Arthralgia","Abdominal pain","Upper respiratory tract infection"]}}